Q2 EPS Estimate for Eton Pharmaceuticals Lowered by Analyst

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Stock analysts at HC Wainwright cut their Q2 2025 earnings estimates for shares of Eton Pharmaceuticals in a research note issued to investors on Wednesday, March 19th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of $0.08 per share for the quarter, down from their previous estimate of $0.17. HC Wainwright has a “Buy” rating and a $33.00 price objective on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.14) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ Q3 2025 earnings at $0.11 EPS, Q4 2025 earnings at $0.18 EPS, FY2025 earnings at $0.42 EPS, FY2026 earnings at $1.57 EPS, FY2027 earnings at $1.85 EPS, FY2028 earnings at $2.87 EPS and FY2029 earnings at $3.74 EPS.

Several other research firms have also recently issued reports on ETON. Craig Hallum increased their price objective on Eton Pharmaceuticals from $23.00 to $26.00 and gave the stock a “buy” rating in a research report on Wednesday. B. Riley reaffirmed a “buy” rating and set a $24.00 price target (up from $21.00) on shares of Eton Pharmaceuticals in a research note on Wednesday.

Eton Pharmaceuticals Trading Down 0.7 %

Shares of ETON stock opened at $14.78 on Friday. The stock has a 50 day simple moving average of $15.56 and a 200-day simple moving average of $11.47. The company has a market cap of $385.03 million, a price-to-earnings ratio of -67.18 and a beta of 1.37. Eton Pharmaceuticals has a 12-month low of $3.03 and a 12-month high of $18.41.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.02). Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%. The firm had revenue of $11.65 million during the quarter, compared to analysts’ expectations of $10.53 million.

Institutional Investors Weigh In On Eton Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Eton Pharmaceuticals during the third quarter worth $54,000. Tower Research Capital LLC TRC acquired a new stake in Eton Pharmaceuticals in the 4th quarter valued at about $86,000. Jane Street Group LLC acquired a new stake in Eton Pharmaceuticals in the 3rd quarter valued at about $90,000. Jefferies Financial Group Inc. purchased a new position in Eton Pharmaceuticals during the 4th quarter valued at about $133,000. Finally, Raymond James Financial Inc. acquired a new position in Eton Pharmaceuticals during the fourth quarter worth about $147,000. Institutional investors and hedge funds own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.